Color Perception in Patients with Schizophreniza and Their Healthy First-degree Relatives: A Cross-sectional Study Authors: Nikita S Shidhore, Vasantmeghna S Murthy, Ajish G Mangot, Sharad V Kshirsagar Published: 2026 ABSTRACT AbstractBackground:Endophenotypic markers are an important area of study for a better understanding of the biological basis of disorders such as schizophrenia. Our study evaluated color vision as a potential endophenotypic marker in schizophrenia.Methods:This was a cross-sectional study at a tertiary care center with 39 patients diagnosed with schizophrenia and 39 healthy first-degree relatives (FDRs). After screening for ocular disorders and color blindness, all participants underwent the Farnsworth–Munsell D-100 test for color perception, the Montreal Cognitive Assessment (MoCA), and a symptom severity assessment with the Positive and Negative Syndrome Scale. Statistical analyses included t tests, correlations, and regression models.Results:All patients demonstrated poor color discrimination (total error score [TES] > 100), compared with 66.7% of FDRs. The mean TES of patients was 225.5 ± 64.3, and that of FDRs was 143.7 ± 50.9, both indicating impaired color discrimination. This deficit was not specific to any one color axis. Patients had significantly lower MoCA scores (20.5 ± 5.1) compared to FDRs (25 ± 2.7) (p < .001). Color perception deficits correlated positively with negative symptom scores (ρ = 0.39, p = .04) and negatively with MoCA scores (ρ = −0.44, p = .005). Regression analysis indicated that cognitive function was the strongest predictor of color perception impairment. Among FDRs, TES correlated significantly with age and MoCA scores.Conclusions:Patients with schizophrenia exhibited marked impairments in color discrimination, and this was shared with FDRs. This suggests that impaired color vision may represent a potential endophenotypic marker of schizophrenia, warranting further longitudinal research.Keywords: Cognition, color discrimination, endophenotype, Farnsworth–Munsell D-100, psychopathology Key Messages: Question: Are color discrimination deficits present in schizophrenia and healthy first-degree relatives (FDRs), suggesting an endophenotypic marker? Question: Are color discrimination deficits present in schizophrenia and healthy first-degree relatives (FDRs), suggesting an endophenotypic marker? Finding: Patients and many healthy FDRs showed impaired color discrimination, which was strongly associated with cognitive dysfunction and negative symptoms. Finding: Patients and many healthy FDRs showed impaired color discrimination, which was strongly associated with cognitive dysfunction and negative symptoms. Meaning: Color vision deficits may represent a shared neurobiological vulnerability and a potential endophenotypic marker for schizophrenia. Meaning: Color vision deficits may represent a shared neurobiological vulnerability and a potential endophenotypic marker for schizophrenia. Schizophrenia is a chronic and disabling psychiatric disorder marked by positive, negative, and cognitive symptom domains. Contemporary understanding of schizophrenia emphasizes a complex interplay between genetic vulnerability and environmental influences. 1 Robust evidence from genome-wide association studies has firmly established the genetic basis of schizophrenia. 2 Endophenotypes are heritable, measurable traits that bridge the gap between genetic risk and clinical expression and have been extensively investigated in schizophrenia and other psychiatric disorders. 3 In schizophrenia, a range of ocular structural and functional abnormalities has been reported, including alterations in retinal vasculature, retinal and macular thickness, as well as impairments in color and contrast perception. 4 Visual processing deficits are consistently described, encompassing abnormalities in motion perception, perceptual organization, scanpath patterns, and color vision. 5 Altered color perception, in particular, has attracted research attention, with several studies documenting deficits among patients with schizophrenia.6–8 Cognitive dysfunction is a core feature of schizophrenia and is evident across multiple domains. An umbrella review reported consistent impairments in working memory, executive functioning, verbal fluency, processing speed, and social cognition, irrespective of treatment status. 9 Cognitive deficits are known to influence sensory processing, suggesting that visual abnormalities in schizophrenia may not be purely sensory in nature but may instead be modulated by higher-order cognitive dysfunction. This interaction underscores the importance of examining visual perceptual deficits within the broader cognitive context of the illness. From a neurobiological perspective, the most widely accepted model of schizophrenia implicates dopaminergic dysregulation, characterized by excess dopamine activity in mesolimbic pathways underlying positive symptoms and relative dopaminergic deficiency in mesocortical circuits associated with negative and cognitive symptoms. In addition, abnormalities in N-methyl-D-aspartate (NMDA) and Gamma-aminobutyric acid neurotransmission have been consistently implicated. 10 Notably, dopamine and NMDA receptors also play critical roles in cone photoreceptor functioning and retinal signal processing. 4 This shared neurochemical substrate provides a plausible biological basis for the co-occurrence of color vision abnormalities in schizophrenia and supports their consideration as potential markers of the illness. Given the chronic and disabling nature of schizophrenia, identifying reliable potential endophenotypic markers is of particular importance for the early detection of individuals at risk and for informing targeted preventive strategies. 11 However, data on visual perceptual abnormalities among unaffected but genetically vulnerable individuals remain limited. First-degree relatives (FDRs) of patients with schizophrenia represent an important population for investigating such markers, as they share genetic risk without manifesting overt psychopathology. Rationale for the Study By examining the relationships among color discrimination, symptom severity, cognitive functioning, and treatment-related variables, we sought to contribute to the growing body of literature on potential endophenotypic markers in schizophrenia. Hypothesis Patients with schizophrenia will demonstrate significantly greater impairment in color discrimination (higher total error scores [TES] on the Farnsworth–Munsell D-100 Hue Test [FMD-100 test]) compared to their healthy FDRs, and this impairment will be significantly associated with psychopathology. Aim To evaluate color discrimination in patients with schizophrenia and their healthy FDRs, and to determine whether color vision abnormalities are shared between these groups. Objectives To assess and compare color vision performance in patients with schizophrenia and their healthy FDRs. To assess and compare color vision performance in patients with schizophrenia and their healthy FDRs. To examine the association between color vision and symptom severity, cognitive functioning, and treatment variables among patients with schizophrenia. To examine the association between color vision and symptom severity, cognitive functioning, and treatment variables among patients with schizophrenia. Methods This cross-sectional study was conducted in the Department of Psychiatry of a tertiary care teaching hospital located in rural India. Data were collected over 2 years from May 2023 to April 2025. Participants were recruited from both outpatient and inpatient psychiatry services. Sample size estimation was guided by findings from Dahdouh et al. 8 who examined color vision in Lebanese patients with schizophrenia and reported a mean TES of 21.45 (SD 6.64) using the Farnsworth–Munsell D-15 test. Sample size calculation was performed using the following formula: where “n” is the required minimum sample size; “z” is the z-score for 95% confidence = 1.96 (rounded to 2); “SD” is the standard deviation of 6.64; “M” is the mean TES of 21.45, and “ε” is the precision of 10%. Substituting these values, we get 39. Hence, we included 39 patients and 39 healthy FDRs of the recruited patients. Ethical Considerations Ethical clearance was obtained from the Institutional Ethics Committee, in accordance with the World Medical Association’s Declaration of Helsinki (Code of Ethics) for experiments involving humans. Eligible patients and their FDRs were recruited after providing written informed consent in their local language. Patients aged 18–45 years who met criteria for schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision, were enrolled by purposive sampling. 12 Forty-seven patients with schizophrenia were found eligible to participate, out of whom eight were not accompanied by an FDR. Hence, they were not enrolled. The FDRs comprised biological parents, siblings, or offspring of patients aged 18–45 years. A cut-off age of 45 years was applied to reduce the likely influence of age-related vision impairments. The FDRs were screened for current or past psychiatric illness through history-taking and clinical examination. Individuals with known color blindness or other retinal or ocular pathology, idiopathic Parkinson’s disease (PD), hallucinogen or stimulant use, adopted or step-relatives, and FDRs with a history of mental illness were excluded. All participants underwent ophthalmological evaluation for retinal pathology and Ishihara testing to rule out frank color blindness. Socio-demographic and clinical information, including duration of illness and antipsychotic dosage converted to chlorpromazine equivalents, was obtained using a semi-structured proforma. Color perception was assessed with the FMD-100. 13 To standardize testing conditions, the assessments were conducted following consultation with the Department of Ophthalmology in a well-lit room with both natural and artificial illumination. Participants were seated adjacent to an unobstructed window, and testing was performed between 11:00 a.m. and 4:00 p.m. under consistent daylight conditions. The participants were provided one color tray at a time, with the loose color caps mixed up and placed outside the tray. They were instructed to arrange the loose caps between the two fixed caps of each tray so that each cap was a close color match to the next until all caps had been placed. In this way, they completed all four-color trays, which were then reviewed for entering the color cap order into the manufacturer-provided FMD-100 software. TES were computed, with scores <16 indicating superior, 16–100 indicating average, and >100 indicating poor color discrimination. Cognitive functioning was evaluated using the Marathi version of the Montreal Cognitive Assessment (MoCA). The MoCA is a clinician-administered screening tool for evaluating cognitive domains such as attention, concentration, short-term memory, working memory, visuospatial abilities, orientation, executive functions, and language. It has 12 questions, with a total score of 30. A score below 26 is considered abnormal. It has been specifically used for screening cognitive impairment in schizophrenia and has been found to correlate well with other established instruments for detecting cognitive impairment in schizophrenia. 14 An official Marathi-translated version 7.1 with good reliability and validity is available from their website https://www.mocatest.org/paper/. Symptom severity in patients was assessed using the Positive and Negative Syndrome Scale (PANSS). 15 The PANSS is a standardized clinical interview used for rating positive symptoms, negative symptoms, and general psychopathology for schizophrenia patients within the last week. It has seven items for positive symptoms, seven for negative symptoms, and 16 for general psychopathology symptoms, each rated on a seven-point scale (1 = absent; 7 = extreme). The total score ranges from 30 to 210. Statistical Analysis Data were entered into Microsoft Excel© and analyzed using Jamovi version 2.6.44. 16 Descriptive statistics, Mann–Whitney U test, Spearman’s correlation coefficients, and regression analyses were performed. Statistical significance was set at p < .05. Data were finally analyzed for 39 patients and 39 FDRs. Results Table 1 summarizes the socio-demographic characteristics of patients with schizophrenia (n = 39) and their FDRs (n = 39). The largest proportion of patients (38.5%) belonged to the 31–40-year age group, whereas most FDRs (33.3%) were aged 21–30 years. FDRs included 17 offspring, 5 parents, and 17 siblings. Among patients, two had comorbid diabetes mellitus, and two had hypertension, while one FDR reported diabetes mellitus. Twelve patients and five FDRs reported tobacco use. Alcohol use was reported by one FDR, with no patients reporting alcohol consumption. Seven patients and six FDRs used spectacles. Table 1.Socio-demographic Profile of Participants.Age (Years), Mean ± Standard DeviationPatients n = 39n (%)FDR n = 39n (%)37.2 ± 6.730.9 ± 9.8Gendern (%)Male21 (53.8)24 (61.5)Female18 (46.2)15 (38.5)Marital statusn (%)Married25 (64.1)20 (51.3)Unmarried12 (30.7)19 (48.7)Widowed1 (2.6)0Divorced1 (2.6)0Occupationn (%)Employed20 (51.3)13 (33.3)Unemployed8 (20.5)19 (48.7)Homemaker11 (28.2)7 (18)Highest formal educationn (%)No formal education3 (7.7)3 (7.7)Standard VIII9 (23)7 (18)Standard X13 (33.3)7 (18)Standard XII7 (18)10 (25.6)Graduation7 (18)12 (30.7)Family structuren (%)Joint9 (23)9 (23.1)Nuclear29 (74.4)30 (76.9)Single1 (2.6)0Current living situationn (%)With family38 (97.4)39 (100)Without family1 (2.6)0FDR: First-degree relative. Socio-demographic Profile of Participants. FDR: First-degree relative. Regarding illness duration, 10 patients had been diagnosed within the preceding year, 17 had a duration of illness of 1–5 years, and 12 had been diagnosed more than 6 years before study enrollment. Based on PANSS total scores, 20 patients were categorized as mildly ill (score < 58), 8 as moderately ill (score 59–75), 8 as markedly ill (score 76–95), and 3 as severely ill (score > 95). PANSS, MoCA, and TES scores are detailed in Table 2. Normal cognitive performance (MoCA ≥ 26) was observed in 5 patients and 22 FDRs. Mild cognitive impairment (MCI) (MoCA 18–25) was present in 24 patients and 16 FDRs, moderate impairment (MoCA 10–17) in 9 patients and 1 FDR, and severe impairment (MoCA < 9) in 1 patient. Table 2.Illness Severity, Cognitive Function, and Color Discrimination Among Participants.VariablePatientsFDRsp ValueM ± SD95% CIM ± SD95% CIPANSS scoreTotalPositive symptomsNegative symptomsGeneral psychopathology61.9 ± 18.315.7 ± 4.918.2 ± 8.428 ± 8.455.9, 67.814, 17.315.5, 20.925.3, 30.8–––MoCA score20.5 ± 5.118.9, 22.125 ± 2.724.1, 25.9<.001*TES FMD-100₹225.5 ± 64.3204.6, 246.3143.7 ± 50.9127.2, 160.2<.001*PANSS: Positive and Negative Syndrome Scale, MoCA: Montreal Cognitive Assessment, TES: Total error score, FMD-100: Farnsworth–Munsell D-100 Hue Test, FDR: First-degree relative, M: Mean, SD: Standard deviation, CI: Confidence interval. *Significant at p < .05 using Mann–Whitney U test. Illness Severity, Cognitive Function, and Color Discrimination Among Participants. PANSS: Positive and Negative Syndrome Scale, MoCA: Montreal Cognitive Assessment, TES: Total error score, FMD-100: Farnsworth–Munsell D-100 Hue Test, FDR: First-degree relative, M: Mean, SD: Standard deviation, CI: Confidence interval. *Significant at p < .05 using Mann–Whitney U test. All patients (100%) demonstrated poor color discrimination (TES > 100), whereas 26 FDRs (66.7%) showed poor discrimination, and the remaining 13 FDRs (33.3%) showed average discrimination (TES 16–100). Figures 1 and 2 depict the sample output of performances on the FMD-100 test from one patient-FDR (sibling) pair. The polar plots show widespread spikes, which indicate a reduction in color discrimination across all color domains-protan, deutan, and tritan. Ambiguous color deficiency was the most frequent pattern observed in both groups, affecting 37 patients and 38 FDRs, while the remaining participants exhibited tritan (blue–yellow) deficiencies. Polar Plot of FMD-100 Test Performance of a 32-year-old Male Sibling. The polar plot of a sibling shows prominent spikes in the cyan–blue spectrum (cap 45), the blue– purple spectrum (caps 52–55), and the purple–pink spectrum (near cap 66) indicating hue confusion. Conversely, the participant demonstrated stable, near-normal discrimination performance within the orange–yellow (caps 1–25) and red–pink (caps 75–85) wavelength regions as the plots stay close to the center of the circle. The calculated TES was 148, indicating poor overall color discrimination. Polar plots of individuals with superior color discrimination (TES < 16) do not demonstrate any obvious spikes. Polar Plot of FMD-100 Test Performance of a 28-year-old Male Patient. The polar plot of the related patient shows prominent hue confusion, evidenced by peaks in the green–yellow (cap 31), blue–purple (cap 54), blue–purple (cap 60), and purple–red (cap 76) spectral regions, reflecting a greater number of errors in color discrimination. The calculated TES was 152, indicating poor overall color discrimination. In the absence of a concurrent local control group, color discrimination in patients and FDRs was compared with the normative cut-offs provided in the FMD-100 test manual. The proportion of participants with TES between 16 and 100 was compared with the established population norm (68%) using a one-sample proportion test. TES distributions differed significantly from population norms in both groups. All patients (100%, n = 39) had impaired color discrimination (TES > 100), representing a marked shift from the expected population distribution (χ²[2] = 204.75, p < .001). Similarly, most FDRs (66.7%, n = 26) demonstrated impaired color discrimination (TES > 100), significantly exceeding population expectations (χ²[2] = 75.71, p < .001) (Table 3). Table 3.Comparison of Patients’ and First-degree Relatives’ TES with the General Population Norm.TES BracketClinical ProfileGeneral Population NormFirst-degree RelativePatient<16Superior discrimination16% (expected: 6.2)0.0% (n = 0)0.0% (n = 0)16–100Average discrimination68% (expected: 26.5)33.4% (n = 13)0.0% (n = 0)>100Impaired discrimination16% (expected: 6.2)66.6% (n = 26) *100.0% (n = 39)*TES: Total error score. *p < .001 (chi-square goodness-of-fit test). Comparison of Patients’ and First-degree Relatives’ TES with the General Population Norm. TES: Total error score. *p < .001 (chi-square goodness-of-fit test). The Shapiro–Wilk test showed that TES, MoCA, PANSS scores, and age were not normally distributed. Compared to FDRs, patients had significantly lower MoCA scores (U = 329, z = −4.33, p < .001, r = .57) and significantly higher error scores on the FMD-100 (U = 226, z = −5.34, p < .001, r = .70), demonstrating a large effect size (Table 2). Correlational analyses among patients are presented in Table 4. Among FDRs, TES showed a significant negative correlation with MoCA scores (ρ [37] = −0.44, p = .005). Age demonstrated a positive correlation with TES in both groups, although this association was not statistically significant among patients (ρ [37] = 0.27, p = .09) but was significant among FDRs (ρ [37] = 0.67, p = < .001). Table 4.Correlation Between Color Perception and Clinical Variables Among Patients.VariableTES ρ p ValuePANSS (total)0.30.06Positive symptom subscale0.17.29Negative symptom subscale0.39.04*General psychopathology subscale0.24.14MoCA−0.44.005*Chlorpromazine equivalents−0.19.320PANSS: Positive and Negative Syndrome Scale, MoCA: Montreal Cognitive Assessment, TES: Total error score, *Significant at p < .05, Spearman correlation coefficient. Correlation Between Color Perception and Clinical Variables Among Patients. PANSS: Positive and Negative Syndrome Scale, MoCA: Montreal Cognitive Assessment, TES: Total error score, *Significant at p < .05, Spearman correlation coefficient. Multiple regression analysis was conducted with TES as the dependent variable. Cognitive functioning, as measured by MoCA score, emerged as the only significant predictor of color discrimination performance (B = –4.85, SE = 2.22, t = −2.18, p = .036), indicating that each one-point increase in MoCA score was associated with an average decrease of approximately 4.85 points in TES. PANSS total score and age were not individually associated with TES. The overall regression model was statistically significant (adjusted R² = 0.25, F[3, 35] = 5.26, p = .004). Medication dosage data were unavailable for 8 of the 39 patients. Of these, 29 received only second-generation antipsychotics, while two received a combination of first- and second-generation antipsychotics; no patient received first-generation antipsychotic monotherapy. Including the chlorpromazine-equivalent dose in the regression model would therefore have substantially reduced the effective sample size due to listwise deletion, resulting in a loss of statistical power and potentially unstable parameter estimates. Hence, it was not included in the final regression model. Discussion Our findings demonstrate a gradient of color discrimination impairment, increasing from 16% in the general population (as per the test manual) to 66.7% in FDRs and 100% in patients. This pattern is consistent with increasing familial liability to schizophrenia and supports impaired color discrimination as a potential subclinical endophenotypic marker. These findings are consistent with a Lebanese study that demonstrated significantly poorer color discrimination in patients with schizophrenia compared with age- and sex-matched healthy controls.7 In that study, patients were chronically hospitalized, markedly more symptomatic, and had substantially higher PANSS total and subscale scores than those in our sample. Despite these differences in illness severity, both studies demonstrated a positive association between PANSS scores and TES. In our sample, TES showed a significant positive correlation specifically with negative symptom severity, a relationship not observed across the entire sample in the Lebanese study. Negative symptoms have been linked to perceptual disturbances arising from dysfunction in the magnocellular visual pathway. 17 Moreover, impairments in both magnocellular and parvocellular pathways, which together contribute to visual processing and color perception, have been documented in schizophrenia. 18 Methodological differences may partly explain variations in findings across studies. Dahdouh et al. (2020) employed the Farnsworth–Munsell D-15 test, a relatively less sensitive measure that does not permit detailed analysis of specific color axes. 7 Their study also did not include FDRs, instead relying on comparisons with healthy controls. In a subsequent publication, the same group reported predominant protan axis abnormalities among a larger sample of patients with schizophrenia. 8 In contrast, our findings indicated that non-specific or ambiguous color discrimination deficits were most common, not only among patients but also among their FDRs, suggesting a broader and less axis-specific impairment. The role of antipsychotic treatment in color vision abnormalities has been explored in earlier studies. Fernandes et al. (2019), using the Cambridge Color Test, reported greater color vision impairment in patients receiving first-generation antipsychotics compared with those on second-generation agents.19 Similarly, Chen et al. (2003) observed that patients treated with first-generation antipsychotics exhibited poorer visual contrast discrimination than those on second-generation antipsychotics, FDRs, and healthy controls. 20 These findings collectively indicate that visual perceptual deficits are common in schizophrenia and may be exacerbated by first-generation antipsychotic treatment. Importantly, color discrimination deficits and MoCA scores in first-episode schizophrenia have been shown to improve following antipsychotic treatment, supporting the view that these perceptual abnormalities are state-related features of the illness. 21 Although our study did not specifically examine differences across antipsychotic classes, the observed negative correlation between chlorpromazine-equivalent doses and TES suggests that higher antipsychotic doses were associated with better color discrimination. This finding raises the possibility that color vision impairments are related to the underlying illness process, potentially mediated by a hyperdopaminergic state in the retinal epithelium, and that symptom improvement—particularly in negative and cognitive domains—may lead to parallel improvements in color perception. Dopaminergic dysfunction may represent a shared biological substrate linking color vision abnormalities with neuropsychiatric and neurodegenerative disorders. Dopaminergic pathways have been implicated in both schizophrenia and PD, conditions in which color vision impairments have been consistently reported. Notably, deficits along the red–green and blue–yellow axes can be detected up to a decade before the onset of motor symptoms in PD. 22 A recent systematic review further supports the presence of color vision deficits in schizophrenia, despite inconsistent associations with symptom severity, highlighting the need for further research in this area. 23 The prevailing neurobiological model of schizophrenia attributes negative and cognitive symptoms to relative dopaminergic hypofunction in mesocortical pathways. 24 Similar dopaminergic imbalances may extend to the retina, contributing to perceptual abnormalities such as impaired color discrimination. 25 In addition, NMDA receptor hypofunction has been implicated in the cognitive deficits characteristic of schizophrenia, which may secondarily affect visual perception.26,27 Evidence from studies demonstrating abnormalities in visual evoked potentials and retinal electrophysiology further supports the presence of disrupted visual signal transmission from the retina to higher cortical regions in schizophrenia. 17 In our study, FDRs performed significantly better than patients on measures of color discrimination, yet their performance remained inferior to existing Indian normative data, with 66.7% demonstrating poor performance on the FMD-100.28,29 The shared presence of color discrimination deficits among patients and their unaffected relatives supports the hypothesis that such impairments may constitute a potential endophenotypic marker of schizophrenia. Cognitive assessment revealed that a majority of patients exhibited MCI, with MoCA scores ranging from 18 to 25, and patients performed significantly worse than FDRs. This finding is consistent with the well-established presence of cognitive dysfunction in schizophrenia.30,31 Notably, a substantial proportion of FDRs also demonstrated MCI. Prior studies using neuropsychological measures such as the Wisconsin Card Sorting Test have shown that both patients and their unaffected siblings perform worse than healthy controls. 32 Schizophrenia has been associated with reduced intellectual ability and progressive, heritable brain volume loss, leading to the hypothesis that unaffected relatives may exhibit subclinical cognitive deficits.33,34 Our findings are in agreement with this conceptual framework. We also observed a significant negative correlation between MoCA scores and FMD-100 performance, indicating that poorer cognitive functioning was associated with greater impairment in color discrimination. This association was moderate in patients and milder but still significant in FDRs. Cognitive domains such as attention, executive functioning, and general intelligence have previously been shown to influence TES performance. 35 Evidence from PD research further underscores the contribution of cognition to visual perception. Patients with PD and MCI demonstrate poorer color discrimination than those without MCI, suggesting that visual perceptual deficits are influenced not only by dopaminergic dysfunction but also by cognitive impairment. 36 That study additionally linked poorer performance to white matter abnormalities, particularly in the right posterior cortical regions. Sensory perception and cognition are closely interrelated, making their effects difficult to disentangle in clinical research. Although less cognitively demanding color vision tests may reduce the influence of cognitive function, they provide a less comprehensive assessment of color discrimination. 37 We therefore selected the FMD-100 test because of its greater sensitivity across a wider range of color hues. Age-related effects on color discrimination were also examined. We identified a positive correlation between age and TES in both patients and FDRs, although this association reached statistical significance only among FDRs. This suggests that age may predict declining color discrimination in unaffected relatives but not in patients with schizophrenia. Previous studies have shown that chromatic sensitivity, particularly in the short-wavelength region, as well as blue–yellow discrimination and visual cognition, decline with advancing age.38,39 In schizophrenia, however, disease-related pathology appears to exert a dominant influence on color discrimination, potentially overshadowing age-related changes. This observation further supports the notion that color vision abnormalities are intrinsic features of the illness rather than merely age-related phenomena. Strengths We employed the sensitive FMD-100 test to assess color discrimination in detail and included healthy FDRs to explore its endophenotypic potential. The integration of cognitive and symptom severity measures, along with ophthalmologic screening, reduced potential confounding. Limitations The cross-sectional design precludes causal inferences, and the modest sample size may limit statistical power. The use of FMD-15 data for sample size estimation, rather than FMD-100 data, is a methodological limitation. However, in the absence of prior FMD-100 studies involving patients with schizophrenia and their FDRs, this represented the most appropriate and pragmatic approach. The requirement for an accompanying FDR may have introduced selection bias, although its impact on the primary outcome is likely to be limited. While findings from patients’ TES are suggestive, the present cross-sectional design and the absence of an unrelated healthy control group cannot establish heritability, trait stability, or cosegregation within families. Lack of stratification by antipsychotic class may also restrict interpretation and generalizability. Conclusions Our findings indicate significant impairment in color perception among individuals with schizophrenia, with milder deficits also observed in their healthy FDRs. These abnormalities appear to be intrinsic to the schizophrenia spectrum, show improvement with antipsychotic treatment, and are shared by genetically related but unaffected individuals. Color vision impairment may therefore represent a potential subclinical endophenotypic marker of vulnerability. Such deficits likely reflect underlying neurobiological alterations associated with psychopathology severity, particularly negative symptoms, and cognitive functioning, highlighting the potential utility of color vision assessment in early detection and longitudinal monitoring. Supplemental Material Supplemental material for this article is available online. Acknowledgments We would like to sincerely thank the faculty and support staff of our University’s Department of Ophthalmology for their full cooperation. Footnotes Reporting Guidelines (Supplementary Online Material): Name: STROBE Citation: von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344–349. DOI: 10. 1016/j.jclinepi.2007.11.008. Data Sharing Statements: Deidentified individual participant data (including data dictionaries) will be made available, in addition to study protocols, the statistical analysis plan, and the informed consent form. The data will be made available upon publication to researchers who provide a methodologically sound proposal to achieve the goals of the approved proposal. Proposals should be submitted to dr.ajish@outlook.com The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Declaration Regarding the Use of Generative AI: No part of this article was written or generated by a generative AI tool. The authors take full responsibility for the accuracy, integrity, and originality of the published article. Ethical Approval: Ethical approval was obtained from the Institutional Ethics Committee of Krishna Vishwa Vidyapeeth (Deemed to be University), Karad, Satara District, Maharashtra, India (Ref. No. KIMSDU/IEC/02/2023, dated 15 March 2023). Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The study was funded by the institute where it was conducted as part of a postgraduate thesis grant awarded to the first author. Informed Consent: Written informed consent was taken from all the study participants. Registration (PROSPERO/WHO-approved Public Trials Registry): Not applicable. Citation Diversity Statement: We are committed to equitable citation practices and have made conscious efforts to include work from authors of diverse genders, geographic regions (including the Global South), career stages, and historically marginalized groups. We aim to support a more inclusive and representative References Associated Data Supplementary Materials Supplemental material for this article is available online.